7th World Congress on Breast Cancer

Landing on this page, a visitor is looking at one edition of a long-running medical conference brand run by Conference Series LLC, the academic-events operator behind hundreds of similarly named gatherings. The 7th World Congress on Breast Cancer was the 2018 instance, held in Frankfurt, Germany, on May 10 and 11. The site itself does not freeze on that past event. By the time anyone reads it now, the same web property is promoting the 16th edition, set for Dubai in late June 2026, under a theme about worldwide insights into breast cancer research and treatment. That tells you the listing is one node in a rolling series, not a standalone summary of a finished symposium, and reading it as the former clears up a lot of the initial confusion about what the page covers.

Program structure across 18 specialized tracks

The clinical scope is wide. The program is built around 18 specialized tracks, and they read like a working table of contents for the field: breast cancer staging, tumor immunology, surgical approaches, clinical trials, and a string of adjacent subtopics. The intended audience is just as broad. Surgeons, oncologists, pathologists, radiologists, radiation therapists, nurses, healthcare educators, policy-makers, and students all appear in the stated target list. A meeting that puts a radiation therapist and a policy-maker in the same room is aiming at the whole care pathway, from the operating table to the funding decisions, and the track list backs that ambition with concrete sessions rather than vague promises. It is worth pausing on that range, because most single-specialty conferences either go deep on the science or wide on the stakeholders, rarely both.

Abstract submission and CME certification

For anyone weighing whether to take part, the practical machinery is laid out. The 7th World Congress on Breast Cancer supports abstract submission and poster presentations, offers CME-accredited certification, and provides DOI-assigned publication opportunities, which means work presented can be cited and tracked afterward. There are sponsorship and exhibition packages for companies, speaker guidelines for presenters, an FAQ section, and venue and hospitality information. A market analysis section sits alongside all this, pegging the breast cancer therapeutics market at 34 billion dollars in 2023, presumably to make the commercial case to potential exhibitors and sponsors. That figure does more for the sales pitch than for a clinician deciding whether the science is worth two days, but it is at least a real, sourced number rather than padding.

Who is the 7th World Congress on Breast Cancer really for? Researchers and clinicians who already operate in the conference economy and understand how these academic-events series work. Someone submitting an abstract, chasing CME credits, or hunting a citable DOI will recognize exactly what is on offer and how to use it. A patient or a family member searching for treatment guidance would be in the wrong place; this is a professional gathering, not a care resource, and nothing on the page pretends otherwise. The 7th World Congress on Breast Cancer is explicit about its audience, and reading the listing with that frame removes most of the friction about what it is and is not.

Organizer reputation and review feedback

Credibility splits along two lines. On organizer reputation, Conference Series LLC is a known and heavily discussed name in academic publishing and events circles. Prospective attendees in this space have long debated its cost-versus-value ratio, and that conversation is easy enough to find with a targeted search. On independent feedback for this specific brand, the picture is sparse. The events platform 10times lists the 2018 Frankfurt edition with a 4.0 rating drawn from two reviews, plus 21 people who marked themselves interested. A separate London edition from 2023 shows a 5.0 from a single review and 50 interested. Two or three ratings are not a meaningful sample. No ratings turned up on Google, Trustpilot, Yelp, the BBB, or other major platforms, so independent public commentary on the 7th World Congress on Breast Cancer is essentially absent.

From organizer claims to verification steps

That absence is not damning on its own. Niche academic conferences rarely accumulate the consumer-style review volume that restaurants or e-commerce shops do, and a blank review record is not evidence of a problem. It does mean a first-time attendee has no crowd-sourced signal to lean on and has to judge the event on its program, its accreditation claims, and the broader track record of the organizer. Anyone considering registration would be well-served by confirming the CME accreditation specifics and the publication arrangements directly, since those are the elements that carry the most professional value and are worth verifying before paying fees.

Contact information accessibility

Contact transparency is a fair, if mild, knock against the 7th World Congress on Breast Cancer. There is a navigation section labeled "Symposium and Contact Details," so the route exists, but specific phone numbers, email addresses, and a physical address are not put front and center on the landing page. A visitor has to click deeper to find them. For a conference asking people to travel internationally and pay registration fees, surfacing a phone line and an address higher up would inspire more confidence than leaving them a layer down. It is not a disqualifier, but easier access would close a real trust gap for a newcomer.

Strengths and limitations of the offering

Weighing the whole picture, the 7th World Congress on Breast Cancer presents as a structured, professionally organized offering within a well-known events series. It is strong on program detail and professional infrastructure: 18 tracks, CME accreditation, and DOI-assigned publication are substantive provisions, not cosmetic ones. The gaps are the limited independent validation and the contact details that require extra clicks. Someone already fluent in how international medical congresses operate will know how to weigh those gaps against the published scientific program. Someone newer to the format should factor in the light review record and the organizer's broader reputation before registering.

The published program of the 7th World Congress on Breast Cancer is detailed enough to evaluate on its own terms, and the 18 tracks and accreditation provisions are the strongest argument for it. Whether the 7th World Congress on Breast Cancer delivers on that program is something the sparse public record cannot yet confirm.